Trichinosis medical therapy

Trichinosis Microchapters
Home
Patient Information
Overview
Historical perspective
Classification
Pathophysiology
Causes
Differentiating Trichinosis from other Diseases
Epidemiology and Demographics
Risk Factors
Natural History, Complications and Prognosis
Diagnosis
Diagnostic Criteria
History and Symptoms
Physical Examination
Laboratory Findings
Other Diagnostic Studies
Treatment
Medical Therapy
Primary Prevention
Secondary Prevention
Cost-Effectiveness of Therapy
Future or Investigational Therapies
Case Studies
Case #1
Trichinosis medical therapy On the Web
Most recent articles
Most cited articles
Review articles
CME Programs
Powerpoint slides
Images
American Roentgen Ray Society Images of Trichinosis medical therapy All Images X-rays Echo & Ultrasound CT Images MRI
Ongoing Trials at Clinical Trials.gov
US National Guidelines Clearinghouse
NICE Guidance
FDA on Trichinosis medical therapy
CDC on Trichinosis medical therapy
Trichinosis medical therapy in the news
Blogs on Trichinosis medical therapy
Directions to Hospitals Treating Trichinosis
Risk calculators and risk factors for Trichinosis medical therapy

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1] Associate Editor(s)-in-Chief: Danitza Lukac

Medical therapy

Trichinosis Anthelmintics Treatment

Drug	Adult and Pediatric Dose
Albendazole	400 mg twice a day by mouth for 8 to 14 days
Mebendazole	200 to 400 mg three times a day by mouth for 3 days, then 400 to 500 mg three times a day by mouth for 10 days

• Prompt treatment with antiparasitic drugs can help prevent the progression of trichinellosis by killing the adult worms and so preventing further release of larvae.
• Once the larvae have become established in skeletal muscle cells, usually by 3 to 4 weeks post infection, treatment may not completely eliminate the infection and associated symptoms.
• Treatment with either mebendazole or albendazole is recommended.
• If treatment is not initiated within the first several days of infection, more prolonged or repeated courses of treatment may be necessary.
• Both drugs are considered relatively safe but have been associated with side effects including bone marrow suppression.
• Patients on longer courses of therapy should be monitored by serial complete blood counts to detect any adverse effects promptly and discontinue treatment.
• Albendazole and mebendazole are not approved for use in pregnant women or children under the age of 2 years.
• In addition to antiparasitic medication, treatment with steroids such as prednisone may be used to relieve muscle pain associated with larval migration.

• Asymptomatic, abortive and mild patients:
  • Administration of anthelmintics
  • Administration of steroids if needed.
• Pronounced and severe patients:
  • Hospitalization
    • Compulsory for severe cases
  • Administration of steroids, anthelmintics and analgesics.
  • Administration of fluids and electrolytes